查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1268945

2023-2030 年全球骨質疏鬆症檢測市場

Global Osteoporosis Testing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球骨質疏鬆症檢測市場預計將實現利潤豐厚的增長，到 2022 年將達到 3.835 億美元，到 2030 年將達到 5.668 億美元。 預計全球骨質疏鬆症檢測市場在預測期內（2023-2030 年）的複合年增長率為 5.1%。 由於 X 射線的日益普及和 X 射線最終用途的日益多□□樣化，預計在預測期內，骨質疏鬆症檢測市場對診斷影像服務的需求將會增加。

例如，2020 年，RadNet 和 Dignity Health 在亞利桑那州成立了一家合資企業。 該合資企業支持 Dignity Health 和 RadNet 目前向患者和目標醫療保健社區提供服務的承諾。 例如，Philips N.V. 將在 2021 年推出一款新的 CT，即 Spectral CT 7500，主要用於精準診斷。

影響全球骨質疏鬆症檢測市場的因素是技術進步和骨質疏鬆症患病率的增加。 骨質疏鬆症是一種隨著時間的推移而惡化的疾病。 結果，骨頭可能變得多孔並容易折斷。 雙能 X 射線吸收測定法，也稱為 DXA 或 DEXA 掃描，是目前診斷骨質疏鬆症的金標準。

然而，產品的高成本預計會阻礙市場增長。 例如，DXA 設備的成本估計超過 100,000 美元，佔與其使用相關的大部分成本。 然而，DXA 比現場檢查更適合實驗室調查。

市場動態

技術的進步帶動了市場的增長，是推動市場增長的主要因素之一。

已使用多種技術來評估骨骼健康，其中最常見的是雙能 X 射線吸收測定法 (DXA)，它可以測量脊柱、臀部或全身。 成像技術的最新進展使骨骼健康評估更快、更準確。

例如，位於馬薩諸塞州貝德福德的 Hologic 的 Discovery QDR 系列骨密度計具有高清即時椎骨評估 (IVA) 功能，可掃描腰椎和胸椎 10 秒以檢測椎骨畸形。我來了。 這使得更多患者被歸類為患有骨質疏鬆症，即使 BMD 結果處於臨界狀態。

醫生可以使用它來快速拍攝圖像並確定是否存在椎骨壓縮性骨折。 這些進步旨在提高 DXA 基礎骨密度系統的效用，以全面評估患者的健康狀況，預計將在預測期內推動骨質疏鬆症檢測市場的增長。

與骨質疏鬆症檢測相關的限制阻礙了市場增長。

DXA 測試無法預測誰會骨折。 儘管 DXA 可有效測量骨密度，但它在脊柱畸形或接受過脊柱手術的人群中的使用有限。

隨著更好的成像掃描儀的發展，準確測量這些骨骼參數對於推進骨折風險評估和告知臨床醫生最佳治療策略至關重要。

此外，雖然所有基於 X 射線的方法都可以測量 BMD，但該參數只能解釋 60%–80% 的骨強度變化，而密度測定技術無法評估骨質流失。我們展示了力學方面 (的微觀結構參數、骨骼幾何形狀、彈性特性） 因此，這些因素可能會阻礙預測期內的市場增長。

COVID-19 影響分析

在 COVID-19 大流行期間，篩查、診斷和治療骨質疏鬆症患者已被證明具有挑戰性。 患者進入代謝性骨科診所的機會被打亂，由於治療延誤導致未來出現問題，尤其是狄諾塞麥患者。

在大流行期間，新發術後脆性和髖部骨折患者的骨質疏鬆症護理質量急劇下降。 因此，全球骨質疏鬆症檢測市場受到 COVID-19 的負面影響。

一些醫學協會提出了在大流行期間促進患者和工作人員安全的建議，包括雙能 X 射線吸收測定法 (DXA) 骨密度測定法。還包括國際臨床骨密度測定聯合會 (ISCD)，該組織已受到影響受到危機的影響，並意識到它處於中斷狀態。

俄烏衝突分析

俄羅斯和烏克蘭之間的衝突中斷了一些用於骨質疏鬆症檢測的設備的供應鏈，增加了消費者的成本並使其難以獲得他們需要的檢測。 這些因素對骨質疏鬆症檢測市場產生了重大影響。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 片段類型
  • 最終用戶的片段
  • 區域摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 技術進步
    • 約束因素
      • 與骨質疏鬆症檢測相關的限制
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第 7 章按類型

  • X光掃描
    • 德克薩
  • FRAX 工具
  • 定量超聲掃描

最終用戶第 8 章

  • 醫院
  • 影像診斷中心
  • 骨科診所
  • 門診手術中心

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 競爭場景
  • 市場分析/份額分析
  • 併購分析

第11章公司簡介

  • 通用電氣醫療
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展
  • DMS Imaging
  • Swissray
  • BeamMed
  • Hologic
  • OSTEOSYS
  • Scanflex Healthcare
  • CompuMed
  • FUJIFILM
  • Trivitron Healthcare

第12章 附錄

簡介目錄
Product Code: MD5018

Market Overview

The global osteoporosis testing market reached US$ 383.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 566.8 million by 2030. The global osteoporosis testing market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The growing adoption of X-rays and the rise in the various end-use applications of X-rays are expected to drive demand for diagnostic imaging services in the osteoporosis testing market during the forecast period.

For instance, in 2020, RadNet and Dignity Health launched a collaborative venture in Arizona. This venture aided in Dignity Health and RadNet's current commitment to provide patients and targeted medical communities. For instance, Philips N.V. launched a newer version of CT in 2021 called Spectral CT 7500, which is primarily used for precision diagnosis.

The factors influencing the global osteoporosis testing market are technological advancements and the increasing prevalence of osteoporosis. Osteoporosis is a disease that can worsen over time. This can cause the bone to become more porous and prone to breaking. Dual Energy X-ray Absorptiometry, also known as a DXA or DEXA scan, is the current gold-standard method for diagnosing osteoporosis.

However, the high cost of the product is expected to hamper the market growth. For instance, the cost of the DXA instrument, which is likely to exceed US$ 100,000, accounts for the majority of the costs associated with its use. However, DXA is better suited to lab-based research rather than field testing.

Market Dynamics

The technological advancements lead to the market's growth and is one of the main factors driving the market growth.

A variety of technologies have been used to assess skeletal health, the most common of which is dual-energy X-ray absorptiometry (DXA), which measures the spine, hip, or entire body. The skeletal health assessment has become faster and more accurate due to recent advances in imaging technology.

For instance, the Hologic, Bedford, MA-based Discovery QDR Series bone densitometer includes High-Definition Instant Vertebral Assessment (IVA), which takes a 10-second scan of the lumbar, thoracic spine to detect vertebral deformities. This allows classifying more patients as osteoporotic, even if their BMD results are borderline.

The physician can use this to take quick images and determine whether there is a vertebral compression fracture. These advancements aim to improve the DXA basic bone density system's utility in assessing overall patient health and are expected to drive osteoporosis testing market growth over the forecast period.

Limitations associated with osteoporosis testing are factors hindering the market growth.

A DXA test cannot predict who will fracture. DXA is of limited use in people with a spinal deformity or those who have had previous spinal surgery, despite its effectiveness in measuring bone density.

Accurate measurement of these skeletal parameters through the development of better imaging scanners is critical to advancing fracture risk assessment and informing clinicians on the best treatment strategy.

Moreover, all the X-ray-based methods provide a measure of BMD but this parameter can explain only 60%-80% of the variability in bone strength, and it has demonstrated other mechanical aspects of the bone (microarchitectural parameters, bone geometry, and elastic properties), which cannot be assessed by densitometric techniques. Thus, these factors will hamper the market growth over the forecast period.

COVID-19 Impact Analysis

During the COVID-19 pandemic, screening, diagnosis, and treatment of patients with osteoporosis proved difficult. Patients' access to metabolic bone clinics has been disrupted, causing future problems due to treatment delays, particularly in denosumab patients.

During the pandemic, the quality of osteoporosis care for patients who suffered a new fragility fracture or hip fracture following surgery deteriorated drastically. Hence, the global osteoporosis testing market was negatively impacted by COVID-19.

Several medical societies provided recommendations to promote patient and staff safety during the pandemic, including the International Society for Clinical Densitometry (ISCD), which recognized that bone densitometry testing with dual-energy x-ray absorptiometry (DXA) has been affected and idled by the crisis.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has caused a disruption of the supply chain for some of the equipment used in osteoporosis testing, increasing costs for consumers and making it more difficult for them to access the necessary testing. These factors have had a significant impact on the osteoporosis testing market.

Segment Analysis

The global osteoporosis testing market is segmented based on type, end user and region.

The X-ray scan segment will be dominated by market players during the forecast period.

The X-ray scan segment accounted for the highest market share accounting for approximately 59.7% of the osteoporosis testing market in 2022. X-ray is very helpful and crucial in the diagnosis of osteoporosis. The key X-ray finding indicative of osteoporosis is the loss of bone mass. The main loss is found in the bony trabecula rather than the cortex. The results of a bone density scan are generally utilized alongside a fracture risk assessment to evaluate the chances of breaking a bone or osteoporosis.

Anyone can get affected by osteoporosis at any age, although post-menopausal older women are at high risk. This is due to the decline of estrogen levels after menopause, which results in low bone density. The more dense the bones are, the less likely and stronger they are to get fractured or broken. Osteoporosis may not show any symptoms until a fracture of the bone.

Geographical Analysis

North America holds a dominant position in the market.

North America held 38.5% osteoporosis testing market share in 2022. The most prevalent bone disease, osteoporosis, which affects roughly 10 million people in the U.S. alone, causes bones to become weak and prone to fractures. According to AMGA Foundation, nearly 54 million Americans have osteoporosis or low bone density, and approximately one in two women and one in four men aged 50 and older will break a bone due to osteoporosis. Fractures often have a devastating effect on patients and lead to billions in direct care costs each year.

Many people with osteoporosis do not know they have the disease until after a broken bone. Unfortunately, recent evidence shows that even after a fracture, less than 15 percent of commercially insured US patients receive treatment for osteoporosis.

Competitive Landscape

The major global players include: GE Healthcare, DMS Imaging, Swissray, BeamMed, Hologic, OSTEOSYS, Scanflex Healthcare, CompuMed, FUJIFILM, and Trivitron Healthcare among others.

Why Purchase the Report?

  • To visualize the global osteoporosis testing market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global osteoporosis testing market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global osteoporosis testing market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by End User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Limitations associated with osteoporosis testing
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. X-Rays Scan*
    • 7.2.1. DEXA
    • 7.2.2. Introduction
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. FRAX Tool
  • 7.4. Quantitative Ultrasound Scans

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospital*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Imaging Centers
  • 8.4. Orthopedic Clinics
  • 8.5. Ambulatory Surgery Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. GE Healthcare*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. DMS Imaging
  • 11.3. Swissray
  • 11.4. BeamMed
  • 11.5. Hologic
  • 11.6. OSTEOSYS
  • 11.7. Scanflex Healthcare
  • 11.8. CompuMed
  • 11.9. FUJIFILM
  • 11.10. Trivitron Healthcare

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us